03/11/2021

Press release

YSIOS CAPITAL’S PORTFOLIO COMPANY AURA BIOSCIENCES PRICES IPO ON NASDAQ.

 

 

 

 

Aura Biosciences, Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long-lasting anti-tumor immunity. The
company has the goal of developing this technology in multiple cancer indications with an initial focus in ocular oncology, a group of rare diseases for which there are no approved drugs.

− Ysios Capital invested in Aura Biosciences’ Series B through Ysios BioFund II Innvierte and has continued to support the company in subsequent financing rounds and the crossover round earlier this year.

− Aura Biosciences is the sixth portfolio company of Ysios to be listed on NASDAQ, and the third one this year.

SAN SEBASTIÁN/BARCELONA November 3rd, 2021 – Ysios Capital, a leading Spanish biotechnology venture capital firm, today announced that its portfolio company Aura Biosciences Inc. has priced its initial public offering (IPO) and is trading on the Nasdaq Global Market (NASDAQ: AURA). This is the third Ysios Capital portfolio company, alongside LAVA Therapeutics (NASDAQ: LVTX) and CVRx Inc (NASDAQ: CVRX), to list on NASDAQ this year.

Aura Biosciences Inc. has announced the pricing of 5,400,000 shares of common stock at a public offering price of $14.00 per share. In addition, Aura has granted the underwriters a 30-day option to purchase up to an additional 810,000 shares of common stock at the initial public offering price less underwriting discounts and commissions. All of the shares are being offered by Aura.

The shares began trading on the Nasdaq Global Select Market on October 29th, 2021, under the ticker symbol “AURA.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aura, are expected to be $75.6 million.

Ysios Capital has been supporting the company since its early days through its active role on the board and has contributed to the company’s growth and progress. In line with Ysios’s investment strategy to support companies over their life cycle as they reach value inflection points, Ysios has also participated in the company’s more recent financing rounds.

Joël Jean-Mairet, Managing Partner at Ysios Capital and responsible for the investment in Aura “At Ysios Capital we support exceptional teams with pioneering science and the drive to change patients’ lives. Aura is clearly an example of a pioneering company led by an outstanding team, with top-notch international investors and the potential for a positive impact on patients and society. We believe Aura’s technology is uniquely positioned to enable the development of therapies for cancers that currently have no effective treatments.”

Cowen, SVB Leerink, and Evercore ISI are acting as joint book-running managers for the offering, and BTIG is acting as lead manager for the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The VDC technology platform is based on the discoveries of NIH Distinguished Investigator Dr. John Schiller of the Center for Cancer Research at the National Cancer Institute. The company has the goal of developing this technology in multiple cancer indications with an initial focus on primary choroidal melanoma, a rare disease for which there are no approved drugs. Aura’s lead product candidate belzupacap sarotalocan (AU-011) is currently in Phase 2 development for the first-line treatment of primary choroidal melanoma, a vision and life-threatening form of eye cancer where the standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. AU-011 was well tolerated in a Phase 1b/2 trial, demonstrating high rates of tumor control and vision preservation.

Future pipeline applications for Aura’s technology include additional ocular oncology indications like choroidal metastases and solid tumor indications like non-muscle invasive bladder cancer. Aura is headquartered in Cambridge, MA. For more information, visit www.aurabiosciences.com or follow us on Twitter.

About Ysios Capital

Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to earlyand mid-stage, highly innovative life science companies bringing life-changing treatments to patients, with a focus on indications with high unmet need. Our diverse international team in San Sebastián and Barcelona is driven by science, with the ambition to transform capital into medical breakthroughs.

Ysios Capital was founded in 2008 and has over €400 million in assets under management through its three funds. For more information, please visit www.ysioscapital.com

Nuevos informes y series de datos: El Capital riesgo Informal en España 2021 / Informe de Impacto Económico y Social del Capital Privado en las operaciones de Middle Market en España. 2018 (ASCRI) / Informe de Impacto Económico y Social de los préstamos otorgados por Enisa

Otros informes destacados: Madurez del Venture Capital en España.  (English version)/ Financiación de startups de Energía en España / El tiempo de las desinversiones en Private Equity en España (English version)

Webcapitalriesgo.com está patrocinada por Quantum Capital Partners 

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos requeridos están marcados *

Publicar comentario